Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Tremblay

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
Journal of Community Health|January 2, 2021
The Impact of Socioeconomic Status on the Clinical Outcomes of COVID-19; a Retrospective Cohort StudyChristine Little, Mathilda Alsen, Joshua Barlow, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|November 17, 2025
Early de-escalation of empiric antibiotic therapy in neutropenic fever: a single-center, retrospective studyZachary Mostel, Michelle Evans, Douglas Tremblay, et al.
Carcinogenesis|February 5, 2019
Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemiaGeetanjali R Kamath, Douglas Tremblay, Alexander Coltoff, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2024
Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor TherapyShivani Handa, Ganesh Sivakumar, Andrew Srisuwananukorn, et al.
Acta Haematologica|June 12, 2025
Ring Chromosomes in Patients with Myeloid Neoplasms are Associated with a Poor Response to TherapyDaniel I Nathan, Ronald Hoffman, Daiva Ahire, et al.
Clinical Advances in Hematology & Oncology : H&O|December 5, 2017
The effect of novel therapies in high-molecular-risk multiple myelomaGuido Lancman, Douglas Tremblay, Kevin Barley, et al.
Leukemia|December 23, 2024
HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosisShivani Handa, Christoph Schaniel, Joseph Tripodi, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 15, 2022
Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML PatientsJessica Caro, Rafael Madero-Marroquin, Nicole Zubizarreta, et al.
Leukemia & Lymphoma|November 13, 2019
Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysisDouglas Tremblay, Amber King, Lihua Li, et al.
Scientific Reports|November 14, 2019
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative NeoplasmsManali Sapre, Douglas Tremblay, Eric Wilck, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Journal of Community Health|January 2, 2021
The Impact of Socioeconomic Status on the Clinical Outcomes of COVID-19; a Retrospective Cohort StudyChristine Little, Mathilda Alsen, Joshua Barlow, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|November 17, 2025
Early de-escalation of empiric antibiotic therapy in neutropenic fever: a single-center, retrospective studyZachary Mostel, Michelle Evans, Douglas Tremblay, et al.
Carcinogenesis|February 5, 2019
Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemiaGeetanjali R Kamath, Douglas Tremblay, Alexander Coltoff, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2024
Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor TherapyShivani Handa, Ganesh Sivakumar, Andrew Srisuwananukorn, et al.
Acta Haematologica|June 12, 2025
Ring Chromosomes in Patients with Myeloid Neoplasms are Associated with a Poor Response to TherapyDaniel I Nathan, Ronald Hoffman, Daiva Ahire, et al.
Clinical Advances in Hematology & Oncology : H&O|December 5, 2017
The effect of novel therapies in high-molecular-risk multiple myelomaGuido Lancman, Douglas Tremblay, Kevin Barley, et al.
Leukemia|December 23, 2024
HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosisShivani Handa, Christoph Schaniel, Joseph Tripodi, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 15, 2022
Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML PatientsJessica Caro, Rafael Madero-Marroquin, Nicole Zubizarreta, et al.
Leukemia & Lymphoma|November 13, 2019
Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysisDouglas Tremblay, Amber King, Lihua Li, et al.
Scientific Reports|November 14, 2019
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative NeoplasmsManali Sapre, Douglas Tremblay, Eric Wilck, et al.
Pageof 11